A Lakewood family will bike in the 20th annual Children’s Hospital Courage Classic to help raise money for the medical center that has treated their son since birth. Stefan and Brenda Van der Steen will take part in the 3-day tour, which passes through Copper Mountain and Leadville for three...
Latest News
CHICAGO, Ill. — COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced today the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CNP-106, an investigational therapy for the treatment of generalized myasthenia gravis (gMG). CNP-106 is a biodegradable...
Kuopio, Finland – A new study identifies alterations in the transcriptomic signatures in human olfactory mucosal cells of individuals with Alzheimer’s disease following SARS-CoV-2 infection, potentially contributing to exacerbated COVID-19 outcomes. The study was conducted at the University of Eastern Finland in collaboration with the University of Helsinki and published...
HOUSTON, TX — Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces that the U.S. Food and Drug Administration (“FDA” or the “Agency”) has accepted its Investigational New Drug (IND) application for...
HOUSTON, Texas — Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today the launch of the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the...
HOUSTON, TX — Coya Therapeutics, Inc., a clinical-stage biotechnology company developing biologics primarily focused on the restoration of regulatory T cell (Treg) immunomodulatory function, announces the presentation of data demonstrating the role of the peripheral immune system in the pathophysiology of Frontotemporal Dementia (FTD) from a biomarker study conducted at...
Houston, TX – The University of Houston College of Pharmacy is included in a $68.5 million funding package from the Cancer Prevention and Research Institute of Texas (CPRIT). Ming Hu, Diana S-L. Chow Endowed Professor of Drug Discovery and Development, and Gregory Cuny, Joseph P. & Shirley Shipman Buckley Endowed Professor...
Researchers from Osaka University develop a collaborative process for involving patients, families and policymakers in the conversation around priorities for rare-disease research Osaka, Japan – Patients with rare diseases have traditionally been the subjects of medical research. However, in recent years, their role has begun to shift from ‘research participants’...
Baltimore, Maryland – The incidence of Creutzfeldt-Jakob disease (CJD), a universally fatal prion disease that progresses rapidly, rose consistently from 2007 to 2020, a study of death certificates showed. CJD codes on death certificates totaled 5,882 during that period, with 51.2% of cases occurring among women, according to John Probasco,...
SAN DIEGO, Calif. — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFYTM (paltusotine) for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY, a selectively-targeted somatostatin receptor type 2...